Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

The S&P 500 climbed roughly 3% to a record close and its first all-time high since February. The Nasdaq Composite rose about 4%, also hitting a fresh record, as investors continued to pile into ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...